Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Otsuka Partner Akebia Files HIF-PH Inhibitor Vadadustat in US
March 31, 2021
- JCR’s MPS I Drug Earns Orphan Status in Europe
March 31, 2021
- Nafamostat Inhalation Drug Now in Clinic for COVID-19: Daiichi Sankyo
March 31, 2021
- Xospata Shows Survival Benefits in Confirmatory AML Study in China, Other Regions: Astellas
March 31, 2021
- With Promotion Halt Lifted, Nichi-Iko Says to Launch Lyrica OD Generics on April 7
March 30, 2021
- Kyowa Kirin Grants All Worldwide Rights for Anti-LIGHT Antibody to Aevi
March 30, 2021
- Ohara Files Methotrexate Antidote in Japan
March 30, 2021
- Xtandi Gets EU Panel Backing for HSPC: Astellas
March 30, 2021
- Eisai Drops Numbers from New Mid-Term Plan; CEO Wants Value-Based Pricing for AD Meds
March 29, 2021
- Myrbetriq Earns US Approval for Pediatric NDO: Astellas
March 29, 2021
- AZ, Fujifilm to Codevelop Case Search System for Lung Cancer Patients Undergoing Chemoradiotherapy
March 29, 2021
- Ono Takes Part in University of California Drug Discovery Consortium
March 29, 2021
- Takeda Files Dengue Vaccine Candidate in Europe
March 29, 2021
- EMA Accepts Regulatory Filing of Enfortumab Vedotin: Astellas/Seagen
March 29, 2021
- Astellas Sees Growth Potential for “Rx+” as Future Bread-and-Butter Biz: EVP
March 26, 2021
- Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well
March 25, 2021
- Kissei Launches PIII Study of Oncolytic Viral Therapy for Bladder Cancer in Japan
March 25, 2021
- Chugai Earns Japan Nod for Blood-Based Genomic Profiling Test
March 24, 2021
- Sumitomo Dainippon Aims to Overcome Latuda Patent Cliff with Sumitovant Products: CSO
March 24, 2021
- Rohto Acquires Olympus’ Regenerative Medicine Unit
March 24, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…